Opthea (ASX:OPT) LT-Debt-to-Total-Asset : 0.75 (As of Jun. 2024)

View and export this data going back to 1991. Start your Free Trial

What is Opthea LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Opthea's long-term debt to total assests ratio for the quarter that ended in Jun. 2024 was 0.75.

Opthea's long-term debt to total assets ratio declined from Jun. 2023 (0.87) to Jun. 2024 (0.75). It may suggest that Opthea is progressively becoming less dependent on debt to grow their business.

Opthea LT-Debt-to-Total-Asset Historical Data

The historical data trend for Opthea's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Opthea LT-Debt-to-Total-Asset Chart

Opthea Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.87

0.75

Opthea Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															-	-	0.87	-	0.75

Opthea LT-Debt-to-Total-Asset Calculation

Opthea's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Jun. 2024 is calculated as

LT Debt to Total Assets (A: Jun. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Jun. 2024 )	/	Total Assets (A: Jun. 2024 )
	=	213.182	/	284.319
	=	0.75

Opthea's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2024 is calculated as

LT Debt to Total Assets (Q: Jun. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Jun. 2024 )	/	Total Assets (Q: Jun. 2024 )
	=	213.182	/	284.319
	=	0.75

Opthea (ASX:OPT) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Opthea LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Opthea's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Opthea Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Opthea Ltd (ASX:OPT) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

OPT:USA UKJ:Germany

Address

650 Chapel Street, Level 4, Suite 0403, South Yarra, VIC, AUS, 3141

Website

https://www.opthea.com

Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.